Plus TherapeuticsPSTV +0.57%26 PB Ratio is 2.51 as of Jul. 01, 2026, which is 434% above its 10-year median of 0.47. GuruFocus rates PSTV with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,229 Biotechnology companies, Plus Therapeutics ranks better than 56.63% on this metric.
Plus Therapeutics Inc stock PB Ratio (=2.5) is close to 5-year high of 2.52.
The historical rank and industry rank for Plus Therapeutics's PB Ratio or its related term are showing as below:
PSTV'
s PB Ratio Range Over the Past 10 Years
Min: 0.01 Med: 0.47 Max: 96.62
Current: 2.51
During the past 13 years, Plus Therapeutics's highest PB Ratio was 96.62. The lowest was 0.01. And the median was 0.47.
PSTV's PB Ratio is ranked better than 56.63% of 1229
companies
in the Biotechnology industry
Industry Median: 2.87
vs PSTV: 2.51
During the past 3 years, the average Book Value Per Share Growth Rate was -78.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Plus Therapeutics was -14.90% per year. The lowest was -78.40% per year. And the median was -63.00% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Plus Therapeutics PB Ratio Related Terms
Plus Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Plus Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Plus Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Plus Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Plus Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Plus Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Plus Therapeutics (PSTV) has a PB Ratio of 2.51 as of Jul. 01, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Plus Therapeutics and its competitors. This is 434% above median its historical median of 0.47. Over the past decade, Plus Therapeutics' PB Ratio has ranged from 0.01 to 96.62. According to the industry distribution chart, Plus Therapeutics ranks #533 out of 1229 companies in the Biotechnology industry, placing it in the top 43.4%.
Is Plus Therapeutics' PB Ratio too high?
Plus Therapeutics' current PB Ratio of 2.51 is 434% above median its 10-year median of 0.47. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 96.62. The Biotechnology industry median PB Ratio is 2.87. Plus Therapeutics' value of 2.51 is 12.5% below this industry median. Based on the distribution chart, Plus Therapeutics ranks #533 out of 1229 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Plus Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Plus Therapeutics' PB Ratio compare to KYNB and VTGN?
According to the Biotechnology industry distribution chart, Plus Therapeutics ranks #533 out of 1229 companies for PB Ratio. This puts Plus Therapeutics in the upper half of its industry. The industry median PB Ratio is 2.87. Plus Therapeutics' value of 2.51 is 12.5% below this benchmark. Historically, Plus Therapeutics' own PB Ratio has ranged from 0.01 to 96.62 over the past decade. While the company's 10-year median is 0.47 vs. the industry median of 2.87, Plus Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.87, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Plus Therapeutics's current PB Ratio of 2.51 is 12.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Plus Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Plus Therapeutics's current PB Ratio is 2.51, which is 434% above median its own 10-year median of 0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Plus Therapeutics stock overvalued right now?
Plus Therapeutics (PSTV) has a current PB Ratio of 2.51. The current PB Ratio is 2.51, which is 434% above median its 10-year median of 0.47 and 12.5% below the Biotechnology industry median of 2.87. Plus Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Plus Therapeutics (PSTV), the current PB Ratio is 2.51 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
26GF Score
Get the complete analysis for PSTV
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PSTV has been successfully added to your 
